A5043563044- Glioma Diagnosis and Treatment
- Cancer Cells and Metastasis
- Axon Guidance and Neuronal Signaling
- CAR-T cell therapy research
- Brain Metastases and Treatment
- Epigenetics and DNA Methylation
- Mechanisms of cancer metastasis
- Cancer Mechanisms and Therapy
- Neurogenesis and neuroplasticity mechanisms
- MicroRNA in disease regulation
- Cancer Genomics and Diagnostics
- 3D Printing in Biomedical Research
- Histone Deacetylase Inhibitors Research
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Single-cell and spatial transcriptomics
- Cancer Research and Treatments
- Tissue Engineering and Regenerative Medicine
- Radiomics and Machine Learning in Medical Imaging
- Microtubule and mitosis dynamics
- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Research Studies
- Ferroptosis and cancer prognosis
- CRISPR and Genetic Engineering
- 14-3-3 protein interactions
McMaster University
2014-2024
Queen's University
2023
McMaster Children's Hospital
2014-2020
Cancer Research Institute of the Slovak Academy of Sciences
2017
Population Health Research Institute
2016
McMaster University Medical Centre
2015
Ontario Institute for Cancer Research
2014-2015
First Hospital of Jilin University
2013
Jilin University
2013
University of Portsmouth
2013
Glioblastoma (GBM) patients suffer from a dismal prognosis, with standard of care therapy inevitably leading to therapy-resistant recurrent tumors. The presence cancer stem cells (CSCs) drives the extensive heterogeneity seen in GBM, prompting need for novel therapies specifically targeting this subset tumor-driving cells. Here, we identify CD70 as potential therapeutic target GBM CSCs.
// Mohini Singh 1, 4 , Neha Garg 6 Chitra Venugopal Robin Hallett 2 Tomas Tokar 7 Nicole McFarlane Sujeivan Mahendram David Bakhshinyan Branavan Manoranjan 3, Parvez Vora Maleeha Qazi Carolynn C. Arpin 10 Brent Page Sina Haftchenary A. Rosa Ping-Shan Lai Rodolfo F. Gómez-Biagi Ahmed M. Ali 11 Andrew Lewis Mulu Geletu Naresh K. Murty John Hassell 2, 4, 5 Igor Jurisica 7, 8, 9 Patrick T. Gunning Sheila 1 McMaster Stem Cell and Cancer Research Institute, University, Hamilton, Ontario,...
Clonal evolution of cancer may be regulated by determinants stemness, specifically self-renewal, and current therapies have not considered how genetic perturbations or properties stemness affect such functional processes. Glioblastoma-initiating cells (GICs), identified expression the cell surface marker CD133, are shown to chemoradioresistant. In study, we sought elucidate role CD133 in self-renewal identify compounds that can target this CD133(+) treatment-refractory population.Using...
Abstract Glioblastoma (GBM) carries a dismal prognosis and inevitably relapses despite aggressive therapy. Many members of the Eph receptor tyrosine kinase (EphR) family are expressed by GBM stem cells (GSC), which have been implicated in resistance to In this study, we identify several EphRs that mark therapeutically targetable GSC population treatment-refractory, recurrent (rGBM). Using highly specific EphR antibody panel CyTOF (cytometry time-of-flight), characterized expression all 14...
Brain metastases (BM) result from the spread of primary tumors to brain and are a leading cause cancer mortality in adults. Secondary tissue colonization remains main bottleneck metastatic development, yet this "premetastatic" stage cascade, when tumor cells cross blood-brain barrier seed before initiating secondary tumor, poorly characterized. Current studies rely on specimens fully developed macrometastases identify therapeutic options treatment, overlooking potentially more treatable...
Brain metastases (BM) are mainly treated palliatively with an expected survival of less than 12 months after diagnosis. In many solid tumors, the human neural stem cell marker glycoprotein CD133 is a tumor-initiating population that contributes to therapy resistance, relapse, and metastasis.
GDNF (glial cell-line-derived neurotrophic factor), and the closely related cytokines artemin neurturin, bind strongly to heparin. Deletion of a basic amino-acid-rich sequence 16 residues N-terminal first cysteine transforming growth factor β domain results in marked reduction heparin binding, whereas removal neighbouring sequence, replacement pairs other with alanine had no effect. The heparin-binding is quite distinct from binding site for high affinity polypeptide receptor, GFRα1 (GDNF...
Multiple sclerosis (MS) is characterized by focal destruction of the white matter brain and spinal cord. The exact mechanisms underlying pathophysiology disease are unknown. Many studies have shown that MS predominantly an autoimmune with inflammatory phase followed a demyelinating phase. Recent alongside current treatment strategies, including glatiramer acetate, revealed potential role for brain-derived neurotrophic factor (BDNF) in MS. However, BDNF not fully understood. We used...
Myelination is critical for normal functioning of mammalian central nervous system. Central system myelin created and maintained by oligodendrocytes. Protein expression patterns change as the oligodendrocyte progenitors differentiate into myelinating Several proteins, including cell surface proteoglycan NG2, proteolipid protein, basic myelin-associated glycoprotein are myelination. The molecular regulation myelination most part unknown, although several transcription factors have been...
Recurrence of solid tumors renders patients vulnerable to advanced, treatment-refractory disease state with mutational and oncogenic landscape distinctive from initial diagnosis. Improving outcomes for recurrent cancers requires a better understanding cell populations that expand the post-therapy, minimal residual (MRD) state. We profile barcoded tumor stem through therapy at initiation, MRD, recurrence in our therapy-adapted, patient-derived xenograft models glioblastoma (GBM). Tumors show...
Despite extensive molecular characterization, human glioblastoma remains a fatal disease with survival rates measured in months. Little improvement is seen standard surgery, radiotherapy and chemotherapy. Clinical progress hampered by the inability to detect target reservoirs based on diffuse invasive pattern presence of phenotypic heterogeneity. The goal this study was stem-like cells that evade first-line treatments using agents capable delivering imaging enhancers or biotherapeutic cargo....
Gene expression profiling of medulloblastoma cells undergoing therapy identifies BPIFB4 as a novel target for recurrent disease.
Brain tumors are typically composed of heterogeneous cells that exhibit distinct phenotypic characteristics and proliferative potentials. Only a relatively small fraction in the tumor with stem cell properties, termed brain initiating (BTICs), possess an ability to differentiate along multiple lineages, self-renew, initiate vivo. This unit describes protocols for culture isolation BTICs. We applied conditions assays originally used normal neural (NSCs) vitro variety tumors. Using...
<div>AbstractPurpose:<p>Brain metastases (BM) are mainly treated palliatively with an expected survival of less than 12 months after diagnosis. In many solid tumors, the human neural stem cell marker glycoprotein CD133 is a tumor-initiating population that contributes to therapy resistance, relapse, and metastasis.</p>Experimental Design:<p>Here, we use variant our previously described binder generate second-generation CD133-specific chimeric antigen receptor T cells...